UnitedHealthcare (UHC) has revised its coverage decision regarding dorsal root ganglion stimulation (DRG-S) following a joint letter submitted in December by AAPM&R and several other pain-related specialties in the Multisociety Pain Workgroup. UHC's updated policy is effective March 1, 2022. This revised policy notes that DRG-S "is proven and medically necessary for treating complex regional pain syndrome (CRPS 1, CRPS 2) when used according to FDA guidelines." AAPM&R continues to work with the Multisociety Pain Workgroup, which functions to unify the voice of several pain management specialties to address coverage issues.